Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction

被引:102
作者
De Luca, Giuseppe [1 ]
Ernst, Nicolette [1 ]
van't Hof, Arnoud W. J. [1 ]
Ottervanger, Jan Paul [1 ]
Hoorntje, Jan C. A. [1 ]
Gosselink, A. T. Marcel [1 ]
Dambrink, Jan-Henk E. [1 ]
de Boer, Menko-Jan [1 ]
Suryapranata, Harry [1 ]
机构
[1] Hosp Weezenlanden, ISALA Klin, Dept Cardiol, NL-8011 JW Zwolle, Netherlands
关键词
D O I
10.1016/j.ahj.2005.06.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Recurrent infarction. after fibrinolytic therapy has been shown to be associated with increased mortality. The aim of this study was to analyze predictors and outcome of reinfarction in a consecutive series of patients undergoing primary angioplasty. Methods Our population is represented by a total of 1955 patients with ST-segment elevation myocardial infarction treated by primary angioplasty between 1997 to 2002. All clinical, angiographic, and follow-up data were prospectively collected. Early reinfarction was defined when two clinical criteria were satisfied within 30 days after the procedure: (1) recurrent ischemic symptoms for > 15 minutes after resolution of symptoms from initial MI; (2) new ST-T-wave changes or new Q waves; (3) reelevation in creatine kinase (CK) or CK-MB to higher levels than normal (or by another 20% if already higher than normal). Results Early reinfarction was observed in 75 (3.8%) patients. At multivariate analysis, advanced Killip class (P =.002), poor preprocedural. TIMI flow (P =.014), administration of IIb-IIIa inhibitors (P =.02), and diabetes (P =.038) were independent predictors of 30-day reinfarction. A total of 107 (5.6%) patients had died. Early reinfarction was associated with a significantly higher mortality (22.7% vs 4.9%, P <.001), even after adjustment for confounding factors (blood pressure, diabetes, Killip class, preprocedural TIMI flow, coronary stenting, multivessel disease, anterior infarct location, preprocedural stenosis, and administration of IIb-IIIa inhibitors) (HR 3.32, 95% CI 1.88-5.84, P <.0001). Conclusions This study showed that, among patients undergoing primary angioplasty for ST-segment elevation myocardial infarction, advanced Killip class at presentation, poor preprocedural TIMI flow, the use of IIb-IIIa inhibitors, and diabetes are independently associated with 30-day reinfarction. Early reinfarction is an independent predictor of 1-year mortality.
引用
收藏
页码:1256 / 1259
页数:4
相关论文
共 21 条
[1]   A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction [J].
Antoniucci, D ;
Rodriguez, A ;
Hempel, A ;
Valenti, R ;
Migliorini, A ;
Vigo, F ;
Parodi, G ;
Fernandez-Pereira, C ;
Moschi, G ;
Bartorelli, A ;
Santoro, GM ;
Bolognese, L ;
Colombo, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (11) :1879-1885
[2]   Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation [J].
Antoniucci, D ;
Valenti, R ;
Migliorini, A ;
Moschi, G ;
Trapani, M ;
Dovellini, EV ;
Bolognese, L ;
Santoro, GM .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (04) :353-357
[3]   Clopidogrel versus ticlopidine after intracoronary stent placement [J].
Berger, PB ;
Bell, MR ;
Rihal, CS ;
Ting, H ;
Barsness, G ;
Garratt, K ;
Bellot, V ;
Mathew, V ;
Melby, S ;
Hammes, L ;
Grill, D ;
Holmes, DR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (07) :1891-1894
[4]   Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].
Bertrand, ME ;
Rupprecht, HJ ;
Urban, P ;
Gershlick, AH .
CIRCULATION, 2000, 102 (06) :624-629
[5]   Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction [J].
Chan, AW ;
Chew, DP ;
Bhatt, DL ;
Moliterno, DJ ;
Topol, EJ ;
Ellis, SG .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) :132-136
[6]   Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study [J].
Davis, TME ;
Fortun, P ;
Mulder, J ;
Davis, WA ;
Bruce, DG .
DIABETOLOGIA, 2004, 47 (03) :395-399
[7]   Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction - A meta-analysis of randomized trials [J].
De Luca, G ;
Suryapranata, H ;
Stone, GW ;
Antoniucci, D ;
Tcheng, JE ;
Neumann, FJ ;
Van de Werf, F ;
Antman, EM ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (14) :1759-1765
[8]   Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty [J].
De Luca, G ;
Ernst, N ;
Zijlstra, F ;
van't Hof, AWJ ;
Hoorntje, JCA ;
Dambrink, JHE ;
Gosslink, ATM ;
de Boer, MJ ;
Suryapranata, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (08) :1363-1367
[9]   Prevalence of silent myocardial ischemia in persons with diabetes mellitus or impaired glucose tolerance and association of hemoglobin A1c with prevalence of silent myocardial ischemia [J].
Deluca, AJ ;
Saulle, LN ;
Aronow, WS ;
Ravipati, G ;
Weiss, MB .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (12) :1472-1474
[10]   Incidence, determinants, and clinical course of reinfarction in-hospital after index acute myocardial infarction (results front the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction [MITRA], and the Myocardial Infarction Registry [MIR]) [J].
Dönges, K ;
Schiele, R ;
Gitt, A ;
Wienbergen, H ;
Schneider, S ;
Zahn, R ;
Grube, R ;
Baumgartel, B ;
Glunz, HG ;
Senges, J .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (09) :1039-1044